SCM
MRSN

Silverarc Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Silverarc Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,732
Closed -$318K – 74
2024
Q3 		$318K Hold
6,732
– – 0.07% 68
2024
Q2 		$338K Buy
6,732
+6,664
+9,800% +$482K 0.08% 66
2024
Q1 		$7.62K Sell
68
-11,996
-99% -$1.19M ﹤0.01% 77
2023
Q4 		$700K Sell
12,064
-20,000
-62% -$805K 0.21% 61
2023
Q3 		$1.02M Sell
32,064
-11,936
-27% -$567K 0.31% 58
2023
Q2 		$3.62M Buy
+44,000
New +$6.44M 1.12% 30

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $135M AUM 36.32% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Silverarc Capital Management's MRSN Position: Q4 2025 in Review

Silverarc Capital Management sold out of Mersana Therapeutics (MRSN) in Q4 2025, closing a stake of 133,636 shares — an estimated $1.04M sold.

Silverarc Capital Management first reported a position in MRSN in Q4 2020 and held it in 16 quarters. The position peaked at $14.9M in Q4 2023. 51 funds tracked by Wall St. Rank hold MRSN as of Q4 2025.

  • Silverarc Capital Management reported no remaining Mersana Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Silverarc Capital Management sold 133,636 Mersana Therapeutics shares in Q4 2025, an estimated $1.04M.
  • Silverarc Capital Management first reported a position in Mersana Therapeutics in Q4 2020 and held it in 16 quarters.
  • Silverarc Capital Management's Mersana Therapeutics position peaked at $14.9M in Q4 2023.
  • 51 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2025.

Based on Silverarc Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.